Dr. Ronzitti is group leader at Genethon. His main interest is the development of AAV-based gene therapies for rare diseases. In 2013, he arrived at Genethon as a post-doc supervised by Dr. Mingozzi to develop a gene therapy approach for Crigler-Najjar syndrome. This approach is now being translated in the clinic. Dr. Ronzitti then moved to the development of gene therapy approaches for glycogen storage diseases. An innovative gene therapy approach for Pompe disease is now in advanced clinical translation. Dr. Ronzitti is also recipient of a Marie Curie fellowship for the development of gene therapy for GSDIII a neuromuscular glycogenosis.